Selling Your Veterinary Practice to Veterinary Practice Partners: A Vet’s 2026 Guide

Key takeaways

• Veterinary Practice Partners (VPP) is a private equity-backed partnership group founded in 2011, headquartered in King of Prussia, Pennsylvania, partnering with general practice hospitals across more than 20 US states.
• Audax Private Equity has owned VPP since 2021 per public deal announcements, after acquiring the platform from Pamlico Capital. CEO John McDonough’s team continued to lead VPP and remained significant owners following the transaction.
• The defining feature is practice-level co-ownership. VPP describes a model where you do not sell your whole practice. VPP takes a majority stake and you keep a direct minority stake in your own hospital, not just in the broader platform.
• The headline cash number is only half the story. When you keep equity in your own practice, the buyout formula, the liquidity timing, and the governance terms on that retained stake matter as much as the dollars at close.
• The most reliable way to know what VPP, or any major buyer, would actually pay and what your retained equity is worth is to run a structured competitive process. We call ours the Elite Selling System: we hand-select and vet every buyer who gets to bid, the way a doorman with a velvet rope lets in only the right people, then run a private bidding window inside that vetted group.

When a vet sits down across the dinner table from me with a VPP conversation in front of them, the first thing I do is slow them down on one word. Sale.

Because with most of the buyer pool, the deal really is a sale: you hand over the practice, you take your check, and whatever happens next happens to someone else’s practice. VPP frames its model differently, and the difference is not cosmetic.

You are not exiting. You are taking on a partner and keeping a piece of your own clinic.

That reframing changes the entire shape of the analysis. The question stops being “is this the highest number I can get for walking away,” and becomes something closer to “do I want to keep co-owning the practice I built, with a partner handling the parts I’d rather not, and a second payday down the road when the platform sells.” Those are different decisions, and they call for a different kind of diligence.

What follows is the same picture I’d lay out over dinner if a vet handed me a VPP term sheet and asked what to make of it. Who VPP is, how the co-ownership model actually works on the page, what it means to keep equity in your own clinic while partnering, where the real negotiation leverage sits, and how to weigh VPP against the rest of the US veterinary buyer pool in a properly run process.

Quick facts on Veterinary Practice Partners

Veterinary Practice Partners was founded in 2011. The platform is headquartered in King of Prussia, Pennsylvania, in the greater Philadelphia area, and partners with general practice veterinary hospitals across more than 20 US states per VPP company materials.

VPP’s network is built around its co-ownership partnership model rather than outright acquisition. The platform has emphasized adding doctor-partners as co-owners over time, and has publicized milestones around the number of associate veterinarians who have transitioned into co-ownership stakes per VPP company announcements.

The ownership history is straightforward but worth knowing. VPP launched in 2011 with backing from Deerfield Management, was later owned by Pamlico Capital, and in 2021 was acquired by Audax Private Equity per public deal announcements at the time.

CEO John McDonough and the management team continued to lead the company and remained significant owners following the Audax investment.

Audax is a middle-market private equity firm with a substantial healthcare services investment practice. The current Audax ownership is the latest chapter in VPP’s PE-backed history, and like any PE sponsor it runs on a fund cycle that points toward an eventual liquidity event.

That detail matters more than usual for VPP sellers, because the co-ownership model means a selling vet often holds equity that participates in that future event.

The single most important fact for a seller evaluating VPP. The model is built around the seller keeping direct equity in their own practice. Per VPP company materials describing the structure, VPP takes the majority stake and the doctor-partner retains a meaningful minority stake in their own hospital. That is structurally different from a clean sale, and it reshapes how the deal should be analyzed.

What VPP actually pays for veterinary practices in 2026

The consistent pattern we see. When a multi-doctor practice gets a direct offer from any major buyer, the structure on the table reflects the leverage the buyer perceives in the room. A single counterparty facing no visible competition has no structural reason to lead with the strongest cash percentage, the most favorable equity split, the tightest buyout-formula protections, or the most generous governance terms on retained equity.

Inside a properly structured competitive process, where the counterparty knows other qualified bidders are underwriting the same practice in parallel, those dimensions tend to move, sometimes meaningfully. The pattern is not unique to VPP.

It is the basic dynamic of how every major buyer in this market calibrates an offer to the room.

VPP does not publish a standard price sheet for any specific practice profile. Per industry M&A commentary (Octus, Capstone Partners, 2025-2026), competitive outcomes for strong multi-doctor general practices in the $2 million-plus revenue range tend to land in the low-teens EBITDA range across the major buyer pool.

EBITDA, for an owner who hasn’t lived in deal language, is what your practice earns in pure operating profit before taxes and accounting choices. The multiple is the multiplier buyers apply to that profit to set the price.

For VPP specifically, that headline range is only part of the math, because of the co-ownership structure. When you sell a majority stake and keep a minority stake in your own practice, the cash at close is calculated on the share VPP buys, not the whole practice.

The retained stake stays on your side of the table and carries its own future value.

For larger multi-location groups ($10 million-plus revenue, $2 million-plus EBITDA), the multiple range generally extends higher than for single-location practices, with deal sizes scaling into the eight-figure-plus range. VPP participates as a partner for practices that fit its model and geography when the profile matches.

For practices below the $2 million revenue threshold or single-doctor practices, the buyer pool generally shifts toward regional PE-backed groups, smaller partnership platforms, and individual buyers. VPP’s model has centered on established practices where a doctor-partner can meaningfully co-own and operate alongside the platform’s support functions.

The cash-at-close reality

Here is where VPP’s model demands a different kind of arithmetic than a straight sale.

In a clean 100-percent sale, the cash at close is measured against the full practice value, with the remainder typically split among earnout and rollover equity. An earnout is part of the price paid later, only if the practice hits agreed targets after closing.

Rollover equity is keeping a slice of ownership in the new entity instead of taking all cash.

With VPP’s co-ownership structure, the cash at close is calculated on the majority stake VPP acquires, and the value you do not take in cash is held as your retained direct stake in your own practice. Per industry M&A commentary across the major buyer pool (Dechert LLP, Holland & Knight, Capstone Partners 2025-2026), the broad pattern is that the majority of acquired-stake value comes as cash at close, with the rest structured around the retained equity and any earnout.

VPP’s specific allocation on any given deal is negotiated case by case.

The practical takeaway is that you cannot compare a VPP offer to a full-cash offer by looking only at the closing wire. You have to value the retained stake too.

A VPP deal that pays a strong number on the majority stake and gives you well-structured equity in your own practice can be worth more over time than a higher all-cash number from a buyer where you walk away with nothing left in the practice. The reverse is also true if the retained-equity terms are weak.

That is the whole game with this model, and it is exactly the kind of side-by-side we build for sellers.

A note on deal structure types in the current market

The broader US veterinary M&A market has shifted measurably toward partnership and joint-venture structures over the past 18 months per MB Law Firm’s 2025 healthcare M&A commentary. In the typical version, the buyer acquires a majority stake (commonly 60 to 80 percent), the seller retains a minority stake (commonly 20 to 40 percent), and a contractual put/call mechanism defines the buyout date and formula price for the retained equity.

VPP sits firmly inside this trend, and arguably ahead of it. The platform has built its identity around the co-ownership idea rather than treating partnership as one structure option among several.

Where VPP’s angle is distinct is the locus of the retained equity. Many partnership and rollover structures give the seller equity in the broader platform or holding company.

VPP’s public framing emphasizes that the doctor-partner co-owns their own hospital directly.

That distinction has real consequences. Equity in your own practice tracks your own practice’s performance most directly, and it can give you a clearer line of sight on the asset you actually understand.

It also raises questions a platform-level rollover does not: how does a future sale of the whole platform flow down to a practice-level co-owner, and what is the relationship between your practice’s value and the platform’s value at the liquidity event. Those are the questions a VPP seller has to get answered in writing.

Our PE pricing guide covers the structure-by-structure comparison in depth.

How VPP’s partnership team operates

VPP’s development team approaches owners through the lens of partnership rather than acquisition, which shapes the early conversations. Per VPP company materials, the platform positions itself to veterinarians who want operational support and growth capital but are not looking to fully exit, and the pitch centers on retained co-ownership and clinical autonomy.

The team works the standard mix of sourcing channels: direct outreach to practice owners, participation in structured competitive sale processes run by qualified sell-side advisors, and inbound inquiries from owners who reach out independently. VPP has also built a de novo arm for veterinarians who want to open new practices under the partnership model per VPP company materials.

A practical implication for sellers. Because VPP’s value proposition leans heavily on the retained equity and the partnership relationship, the early conversation can feel less transactional and more relational than a straight-sale pitch.

That is genuinely part of the model, and for the right owner it is a real draw. It also means the most important economics, the terms on the equity you keep, often get less airtime in those early conversations than the cultural fit.

A well-run sell-side process keeps the warm partnership framing while making sure the retained-equity terms get the scrutiny they deserve. That isn’t unique to VPP; relationship-forward buyers across the pool benefit from the same discipline on the seller’s side.

How VPP integrates the practices it partners with

VPP’s integration model is framed around supporting the local practice while the doctor-partner stays in the ownership seat.

Retained clinical autonomy and local identity. Per VPP company materials, the partnership model emphasizes that doctor-partners keep clinical autonomy and their local brand identity. Practices typically retain their name and customer-facing identity, with the platform supporting rather than absorbing the local practice.

This contrasts with Mars-affiliated entities, which more commonly transition acquired practices to a Mars-network brand over time.

Shared operational support. Per VPP company materials, the platform provides support across learning and development, HR and recruiting, marketing, technology, and finance. The framing is that these functions free the doctor-partner to focus on medicine and culture while the platform handles the back office.

Procurement and platform scale. Like any multi-practice platform, VPP can bring purchasing leverage and operational infrastructure that an independent practice cannot match on its own. The flip side for a co-owner is that platform-level decisions on vendors, systems, and cost allocation can affect the economics of your own practice, which is precisely why the governance and information rights on your retained stake matter.

The co-ownership alignment. The structural argument VPP makes is that keeping the doctor as a direct co-owner aligns incentives. You benefit when your practice does well, because you still own a piece of it.

For the right owner that alignment is real and valuable. The terms that govern the stake are what determine whether the alignment translates into dollars at the buyout, which is the central thing to negotiate.

Doctor relationships. Per industry M&A commentary on PE-backed veterinary acquirers, selling owners commonly stay on in a continuing clinical or leadership role for a multi-year post-close period, with compensation structured as base salary plus production bonus. Under a co-ownership model, that ongoing role sits alongside the retained equity stake.

VPP’s specific post-close employment and equity terms for any given deal are negotiated case by case under the definitive agreement.

VPP’s recent activity in 2025-2026

VPP enters 2026 as an active partnership-model platform in the US veterinary buyer pool. Capstone Partners‘ April 2026 Pet Sector M&A Update documents the broader sector acceleration heading into 2026, with both PE-backed and strategic acquirers running active pipelines.

VPP has publicized continued expansion of its partner-hospital network and growth in the number of doctor-partners who hold co-ownership stakes per VPP company announcements, alongside its de novo program for new practice builds.

The practical takeaway for an owner receiving 2026 VPP outreach: this is a buyer running a sustained partnership-focused program, not a recent entrant testing the model. The co-ownership structure is the platform’s core identity rather than an occasional alternative, and the offer in your hand should be evaluated through that lens, which means valuing the equity you would keep, not just the cash you would take.

Have an offer from VPP? Get a Free Practice Value Estimate — send us the offer and we’ll decompose the terms, value the equity you’d keep in your own practice, and project what your practice would likely clear across the full qualified buyer pool. No upfront cost, no obligation.

How VPP compares to the other major buyers

If you’re considering VPP, you’re probably weighing them implicitly against the other buyers who would compete for your practice. Here’s how VPP stacks up across the dimensions that matter, with the co-ownership angle front and center.

Versus Mars Veterinary Health (VCA, BluePearl, Banfield). Mars is the strategic family-owned exception in the US veterinary buyer pool per Mars company disclosures, distinguishing it from VPP’s PE-backed structure. The deeper contrast is the model itself: Mars-affiliated deals are typically acquisitions, while VPP is built around the seller keeping direct practice-level equity.

Our Mars Veterinary Health buyer profile covers the Mars-specific dimensions in depth.

Versus NVA (JAB Holdings). NVA is owned by JAB Holdings, a privately held long-hold investment vehicle, which creates a different ownership horizon than VPP’s PE-fund cycle. Both preserve local practice identity per their respective company materials.

The structural choice for a seller is whether they want a long-hold platform relationship or a co-ownership stake in their own practice with a defined liquidity event ahead. Our NVA buyer profile walks through the NVA-specific dimensions.

Versus AmeriVet Veterinary Partners. AmeriVet has publicly emphasized a partnership and joint-venture approach with a dual-sponsor PE structure. Both AmeriVet and VPP center retained equity, which makes them natural head-to-head competitors for partnership-minded sellers.

The distinction worth probing is where the equity lives and how the buyout flows: VPP’s public framing emphasizes co-ownership in your own hospital, and the comparison comes down to the specific equity, governance, and liquidity terms each puts on the table. Our AmeriVet buyer profile covers the partnership-model dimensions.

Versus VetCor (Harvest Partners). VetCor is one of the longer-tenured PE-backed platforms, with a brand-preservation, more-traditional rollover posture. The choice between VetCor and VPP often comes down to whether the seller wants a longer-tenured platform with a refined integration playbook or a co-ownership model centered on direct equity in their own practice.

Our VetCor buyer profile covers the institutional-depth dimensions.

Versus the other PE-backed groups (PetVet, Thrive Pet Healthcare, Alliance Animal Health, Mission Pet Health, others). Each has its own integration philosophy and target profile, and several offer partnership or rollover variants of their own. Smaller and newer groups sometimes structure more aggressively for practices that fill specific geographic gaps.

The right way to find out who offers the best total package, cash plus retained-equity value, is to put them in a competitive process and let them surface their best terms in parallel.

What to negotiate before partnering with VPP

Six priorities when negotiating with VPP, with the retained-equity terms as the highest-leverage category given the co-ownership model.

Retained-equity terms (highest priority). Because you keep a direct stake in your own practice, the terms on that stake are the heart of the deal. Negotiate: a clear buyout formula and date, a defined relationship between your practice’s value and the platform’s value at the liquidity event, governance and information rights so you can actually see what you co-own, anti-dilution protection so future platform capital raises do not quietly shrink your stake, and explicit clarity on how a sale of the whole platform flows down to a practice-level co-owner.

A strong headline number with weak equity terms can be worth less over time than the reverse.

Cash at close on the acquired stake. Push for a strong cash percentage on the share VPP buys. Every dollar taken as cash at close is guaranteed money, independent of what happens to the retained stake later.

A competitive process generally supports more flexibility here.

The equity split. The proportion VPP takes versus what you keep drives everything downstream. Negotiate the split with full visibility into how each side is valued, and understand what a larger retained stake means for both your future upside and your future obligations as a co-owner.

Post-sale clinical autonomy. VPP’s model is built on autonomy, but “general approach” language in marketing materials is not the same as contractual commitment. Negotiate explicit language: you make the medicine decisions, with a clear definition of which business decisions stay with you as a co-owner versus migrating to the platform.

Non-compete scope. Non-competes commonly run several years and cover a defined geographic radius. Negotiate shorter duration, a tighter radius, and clarity on how the non-compete interacts with your status as a continuing co-owner of the practice.

Brand and identity in writing. VPP’s materials emphasize that doctor-partners keep their local identity. Get it in the definitive agreement anyway: practice name, signage, website, and marketing materials, even though it aligns with VPP’s stated model.

The keep-ownership-in-your-own-clinic question, in depth

For sellers evaluating VPP specifically, the most useful frame is to think carefully about what it actually means to keep ownership in your own clinic while partnering, rather than selling and walking away.

The case for co-ownership. The argument is real and worth taking seriously. You take meaningful cash off the table now, you offload the operational burden you’d rather not carry, and you keep a stake in the practice you understand better than anyone.

The benefits compound for the right owner:

• You get a second potential payday when the platform reaches its liquidity event, on top of the cash at close
• Your retained stake tracks the performance of the practice you continue to influence as a working co-owner
• You keep clinical autonomy and local identity while gaining back-office support
• The incentive alignment is genuine, because you still own a piece of the upside you help create
• You are not making a clean break from your life’s work on day one

The case for treating co-ownership as a set of terms to scrutinize. The flip side is that “co-ownership” is only as good as the documents that define it. The phrase is attractive; the value lives in the fine print:

• The buyout formula determines what your retained stake is actually worth at exit, and a poorly drawn formula can undervalue it
• The relationship between your practice’s value and the platform’s value at the liquidity event is often where the real money is decided
• Without strong governance and information rights, you can be a co-owner with little visibility into what you co-own
• Platform-level decisions on cost allocation, vendors, and capital can affect your practice’s economics and therefore your stake
• Anti-dilution protection determines whether future platform fundraising quietly erodes your share

The balance between these dimensions is exactly what gets negotiated in the definitive agreement. Sellers who go into a VPP conversation with a refined sell-side process, and other qualified buyers at the table, consistently land more favorable retained-equity terms than sellers who negotiate the partnership one-on-one on the platform’s standard template.

Should I take a VPP offer or run a competitive process?

For VPP specifically, the value of the competitive process is concentrated in two places: the retained-equity terms and the proper valuation of the whole package. The cash-at-close number on the acquired stake may not swing dramatically without competition, but the terms governing your retained equity almost certainly will, because those terms are where a single counterparty’s standard template most favors the platform.

The mechanical reason is the same as for any major buyer. Without competition, no counterparty has incentive to soften the pre-set defaults in their standard documents, and with a co-ownership model those defaults sit largely in the equity and governance clauses.

With competition, every term becomes negotiable, because every bidder knows the seller has alternatives, including full-cash buyers who would let the seller walk away clean.

A competitive process also does something specific for a co-ownership decision: it forces an honest valuation of the retained stake against the alternative of taking all cash from a different buyer. That comparison is hard to make in a vacuum and straightforward when several real offers sit side by side.

VPP participates in well-run competitive processes, and the retained-equity terms get sharper attention from the VPP team when they know qualified competitors are at the table on the same practice in the same window.

What our Elite Selling System actually does

For a VPP-style co-ownership transaction, our process runs differently than it does for a straight-sale buyer, because the negotiation surface lives in the equity and governance clauses rather than the headline multiple.

Phase one — the retained-equity audit. Before any bidder packet goes out, we model what the co-ownership stake is actually worth under different buyout formulas, liquidity timelines, and platform-value relationships. We deconstruct VPP’s standard partnership template against the partnership and rollover templates we’ve seen across the rest of the buyer pool.

Where do the buyout mechanics sit? What governance and information rights are in the draft, and what’s missing?

How does a platform sale flow down to a practice-level co-owner? This audit identifies the leverage points before the process opens.

Phase two — the bidder mix. From the 42-plus named veterinary consolidators TE actively tracks, we invite only the ones that legitimately compete for this specific practice. The partnership-and-equity buyers (AmeriVet, the other partnership-emphasis platforms) compete directly on retained-equity terms.

The full-cash and traditional-rollover buyers (Mars where the practice fits, the longer-tenured PE-backed platforms) compete by giving the seller a clean-exit benchmark to value the VPP stake against. The right mix is typically 5 to 7 invited bidders, each genuinely competing on a dimension the seller cares about.

Phase three — the total-package comparison. Bidders return their full term sheets, not just the headline numbers. The seller sees side-by-side comparisons across cash at close, retained-equity value and terms, buyout mechanics, governance rights, post-sale role, clinical autonomy, brand handling, and the clean-exit alternative.

The seller chooses on the dimensions that matter: sometimes the co-ownership package with the best equity terms (VPP-style), sometimes the highest all-cash number, sometimes the structure that fits their plans for the next five years.

The economic result holds across deal types: practices in the qualifying revenue band that run our process consistently clear materially better total economic outcomes, typically multiple seven figures, sometimes more, than the same practice would have cleared by signing the original direct term sheet without exploring the field.

Closing thought

The honest read on VPP: the co-ownership model is a genuinely distinct offer in the US veterinary buyer pool, and for the right owner it answers a real question. Not every vet wants to sell their life’s work and disappear.

Keeping a direct stake in your own clinic, with a partner handling the operational weight and a second payday potentially ahead, is an attractive middle path between holding on alone and exiting entirely.

What separates a well-negotiated VPP partnership from a mediocre one is not the headline cash number. It is the terms on the equity you keep.

The buyout formula, the liquidity timing, the governance and information rights, the anti-dilution protection, the way a platform sale reaches a practice-level co-owner. Those terms decide whether “co-ownership” becomes real second-bite value or a comforting phrase that doesn’t pay out.

If you’ve received a VPP offer, or if their team has reached out about a partnership, the highest-leverage move is to value the equity you’d keep and see how the rest of the field, including buyers who’d let you walk away clean, would structure the same practice, before committing to anything. Get a Free Practice Value Estimate and we’ll lay out the same total-package comparison we’d build for a client across a dinner table.

Sources

Industry M&A research and valuation data

1. Capstone Partners. Pet Sector M&A Update — April 2026. Capstone Partners industry research.
2. Octus. Veterinary Services Roll-Up Coverage, 2025-2026. Octus credit research and industry commentary.
3. Dechert LLP. Healthcare M&A: 2025-2026 Trends and Outlook. Dechert healthcare practice publications.
4. Holland & Knight. Healthcare Private Equity 2025-2026 Commentary. Holland & Knight healthcare practice publications.
5. MB Law Firm. 2025 Healthcare M&A Trends — Joint Venture and Partnership Structures. MB Law Firm healthcare publications.

Veterinary Practice Partners and parent company materials

6. Veterinary Practice Partners. A True Veterinary Partnership Model; About VPP and co-ownership model. VPP company materials, 2024-2026. vetpracticepartners.com
7. Audax Private Equity. Audax Private Equity Announces Strategic Investment in Veterinary Practice Partners. 2021. audaxprivateequity.com
8. Pamlico Capital. Pamlico Capital Announces Sale of Veterinary Practice Partners (VPP). 2021. pamlicocapital.com

Veterinary practice operations, benchmarks, and profession data

9. iVET360. State of the Veterinary Industry — 2026 Industry Report. iVET360 industry research.
10. American Veterinary Medical Association (AVMA). 2026 AVMA Veterinary Economic Report. AVMA economic research.